Key facts
- This page summarizes Hunter C. Smith's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 May 2026, 16:15.
Hunter C. Smith - 18 May 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RYTM
- Reported as of
- 18 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 May 2026, 16:15:19 UTC
- Prior SEC filing
- 02 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Hunter C. Smith filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 20 May 2026.
Change
- Previous filing in this sequence was filed on 02 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001636385
Primary reporting owner
Smith Hunter C
- Relationship
- Chief Financial Officer
- Address
- C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON
- Signature
- /s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith
- Signature date
- 20 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RYTM
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,000
- Change %
- +2.6%
- Price
- $17.87*
- Shares after
- 119,611
- Date
- 18 May 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RYTM
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -3,000
- Change %
- -3.7%
- Price
- $0.000000*
- Shares after
- 79,000
- Date
- 18 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,000
- Exercise price
- $17.87
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options are fully vested.